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Background: The prevalence of dementia in Parkinson disease (PD) increases
dramatically with advancing age, approaching 80% in patients who survive 20 years
with the disease. Increasing evidence suggests clinical, pathological and genetic overlap
between Alzheimer disease, dementia with Lewy bodies and frontotemporal dementia
with PD. However, the contribution of the dementia-causing genes to PD risk, cognitive
impairment and dementia in PD is not fully established.
Objective: To assess the contribution of coding variants in Mendelian dementia-causing
genes on the risk of developing PD and the effect on cognitive performance of PD
patients.
Methods: We analyzed the coding regions of the amyloid-beta precursor protein (APP),
Presenilin 1 and 2 (PSEN1, PSEN2), and Granulin (GRN) genes from 1,374 PD cases
and 973 controls using pooled-DNA targeted sequence, human exome-chip and whole-
exome sequencing (WES) data by single variant and gene base (SKAT-O and burden
tests) analyses. Global cognitive function was assessed using the Mini-Mental State
Examination (MMSE) or the Montreal Cognitive Assessment (MoCA). The effect of coding
variants in dementia-causing genes on cognitive performance was tested by multiple
regression analysis adjusting for gender, disease duration, age at dementia assessment,
study site and APOE carrier status.
Results: Known AD pathogenic mutations in the PSEN1 (p.A79V) and PSEN2 (p.V148I)
genes were found in 0.3% of all PD patients. There was a significant burden of rare, likely
damaging variants in the GRN and PSEN1 genes in PD patients when compared with
frequencies in the European population from the ExAC database. Multiple regression
analysis revealed that PD patients carrying rare variants in the APP, PSEN1, PSEN2,
and GRN genes exhibit lower cognitive tests scores than non-carrier PD patients (p =
2.0 × 10−4), independent of age at PD diagnosis, age at evaluation, APOE status or
recruitment site.
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Conclusions: Pathogenic mutations in the Alzheimer disease-causing genes (PSEN1
and PSEN2) are found in sporadic PD patients. PD patients with cognitive decline
carry rare variants in dementia-causing genes. Variants in genes causing Mendelian
neurodegenerative diseases exhibit pleiotropic effects.
Keywords: Parkinson disease, dementia, cognitive impairment, rare variants, APP, PSEN1, PSEN2, GRN
INTRODUCTION
Recent genome-wide association studies (GWAS) have reported
an overlap between Parkinson disease (PD) and the most
common forms of dementia including Alzheimer disease (AD),
dementia with Lewy bodies (DLB) and Frontotemporal dementia
(FTD) (Guerreiro et al., 2015; Ferrari et al., 2017). Multiple
variants associated with PD risk have also been identified as
risk factors for AD, DLB, or FTD including variants in the
following genes: Triggering receptor expressed on myeloid cells 2
(TREM2), Microtubule-associated protein tau (MAPT), C9orf72,
Glucocerebrosidase (GBA), andApolipoprotein E (APOE) (Parsian
et al., 2002; Harms et al., 2013; Davis et al., 2015; Benitez et al.,
2016).
AD is the most common form of dementia and is
characterized pathologically by the accumulation of amyloid
plaques and neurofibrillary tangles. Amyloid protein precursor
(APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) mutations
cause autosomal dominant forms of early-onset AD (Cruts et al.,
2012). Approximately 220 pathogenic mutations in the PSEN1
gene have been reported in AD patients worldwide, whereas 27
and 16 pathogenic mutations have been described in theAPP and
PSEN2 genes, respectively (Cruts et al., 2012). Rare functional
variants inAPP (Schulte et al., 2015) and pathogenicmutations in
PSEN1, and PSEN2 have been also reported in PD patients (Takao
et al., 2002; Jimenez-Escrig et al., 2004; Puschmann et al., 2009;
Niwa et al., 2013). We recently reported the presence of leucine-
rich repeat kinase 2 (LRRK2), p.G2019S mutation in members
of two multigenerational families with AD and a suggestive
association of variants in the PTEN-induced putative kinase 1
(PINK1) gene with AD (Fernández et al., 2017). These results
suggest a genetic overlap between familial AD and PD.
There is also an overlap of neuropathology in the brains of
AD and PD patients. Approximately 50–60% of the sporadic and
familial AD patients with pathogenic mutations in APP, PSEN1,
or PSEN2 genes exhibit widespread α-synuclein pathology
(Meeus et al., 2012a). Abnormal cortical amyloid-beta (Aβ)
deposition is present in 60% of PD patients with dementia
(Kotzbauer et al., 2012), the burden of Aβ plaques inversely
correlates with cognitive status in PD cases with dementia (Irwin
et al., 2013) and the progression of the dementia in PD correlates
with Lewy body (LB) and cortical AD-type pathology (Compta
et al., 2011). In addition, AD-like changes in cerebrospinal fluid
(CSF) biomarkers (Aβ levels) have been reported in PD patients
(Terrelonge et al., 2015). Taken together, these results suggest that
abnormal APP processing and Aβ accumulation occurs in PD.
Here, we evaluate the genetic variation ofAPP, PSEN1 and PSEN2
genes in PD patients.
FTD may cause up to 10% of all cases of dementia and
is the second most common cause of early-onset dementia
(<65 years of age) (Ratnavalli et al., 2002). The three most
common genetic causes of FTD are mutations in the genes
MAPT and granulin (GRN), and expansions of a hexanucleotide
repeat (GGGGCC) in the C9orf72 gene. C9orf72 expansions
cause 5–12% of all FTD and 10–35% of familial FTD. MAPT
or GRN mutations are found in 1–10% of all FTD and 5–
25% of familial FTD. MAPT variants associated with FTD
also increase the risk of developing PD (Pastor et al., 2000;
Benitez et al., 2016). C9orf72 expansions have been found in
PD patients in some (Baizabal-Carvallo and Jankovic, 2016)
but not all studies (Harms et al., 2013). Parkinsonism precedes
the cognitive and behavioral symptoms of FTD by several
years in patients with mutations in GRN (Baizabal-Carvallo
and Jankovic, 2016). Up to 41% of FTD patients with GRN
mutations exhibit parkinsonism (Josephs et al., 2007). In
addition, GRN pathogenic mutations have been reported in PD
patients (Brouwers et al., 2007; Rovelet-Lecrux et al., 2008).
Here, we explore the role of variants in the GRN gene in PD
patients.
PD is the most common neurodegenerative movement
disorder, affecting ∼1–2% of people over 60 years of age
(Wright Willis et al., 2010). Clinically, PD patients exhibit
bradykinesia, rest tremor, rigidity, and disturbances in balance.
PD is characterized neuropathologically by the presence of
α-synuclein-positive neuronal inclusions, commonly referred
to as LBs and Lewy neurites, as well as neuronal loss in
the substantia nigra. Genetically, familial autosomal dominant
PD is caused by highly penetrant mutations in the alpha-
synuclein (SNCA) and LRRK2 genes, whereas autosomal recessive
PD is caused by mutations in the PARK2/PARKIN, PINK-
1, and PARK7/DJ-1 genes (Petrucci et al., 2014). Recently,
a GWAS identified at least 41 loci associated at genome-
wide significant level with disease risk in individuals of
European ancestry (Chang et al., 2017). The most statistically
significant signals associated with PD are common variants
located close to SNCA, MAPT, and GBA genes (Chang et al.,
2017).
Dementia is one of the most common non-motor symptoms
in PD (Foltynie et al., 2004; Emre et al., 2007). The prevalence
of dementia in PD patients at any stage of disease ranges
from 22 to 48% (Foltynie et al., 2004; Emre et al., 2007).
Several risk factors for dementia in PD include severity of
parkinsonism, the presence of non-motor symptoms, older age,
male sex and presence of cognitive symptoms at PD diagnosis
(Aarsland and Kurz, 2010). Relatives of PD patients exhibit
a higher risk of dementia than relatives of control subjects,
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(Rocca et al., 2007) supporting a role of genetic factors in
the development of dementia in PD. However, the genetic
contributors to dementia in PD have yet to be fully established.
Longitudinal studies have shown that the APOE ε4 allele, the
H1 haplotype in MAPT and mutations in the GBA gene are
associated with a more rapid cognitive decline in PD (Morley
et al., 2012; Collins and Williams-Gray, 2016; Liu et al., 2016).
In contrast, a cross-sectional study showed that PD carriers of
the LRRK2,p.G2019S mutation exhibit lower rates of dementia
(Srivatsal et al., 2015). However, it is not clear how frequently
mutations in dementia-causing genes occur in PD patients
or whether variants in these genes relate to dementia in PD
patients.
Here, we performed a systematic screening of known
dementia-causing genes (APP, PSEN1, PSEN2, or GRN genes) in
821 PD cases and 423 controls from North America in addition
to 553 PD patients and 550 healthy controls from Spain.
MATERIALS AND METHODS
Subjects
Three cohorts were included in this study: the Washington
University in Saint Louis (WUSTL) Movement Disorder Center
(MO, USA), the Parkinson’s Progression Markers Initiative
(PPMI) consortium (www.ppmi-info.org) and the Movement
Disorders Unit at the University of Navarra (UN), School of
Medicine (Navarra, Spain). PD clinical diagnoses were based
on UK Brain Bank criteria (Hughes et al., 1992). Written
informed consent was obtained from all participants prior
to their enrollment. The Washington University in Saint
Louis Human Research Protection Office (approval number:
201107095) approved the study. Demographic characteristics
of these three populations have been published previously
(Weintraub et al., 2013; Davis et al., 2015; Benitez et al., 2016).
TheWUSTL cohort included 490 non-hispanic white (NHW) PD
cases [64% males, mean ± SD age at onset (AAO) 60 ± 11 years
and 10% had family history of PD] and age- and population-
matched 289 controls (64.8± 10.2 years; mean± SD). The PPMI
cohort was composed of 331 NHW PD cases (50% males, AAO
61 ± 11 years, 9% had family history of PD) and 134 age- and
population-matched controls (60.9 ± 11.4 years). Finally, the
UN cohort was composed of 553 Spanish PD cases (59% males,
AAO 60 ± 9 years, 20% had family history of PD) and 550
healthy Spanish age-matched controls (62 ± 7 years). Only one
member of each family with PD was included in the analyses. All
individuals carrying pathogenic mutations in LRRK2, p.G2019S
(8 PD cases WUSLT), PARK2, p.D53X (1 PD case WUSTL), or
PINK, R492X1(1 PD case WUSTL) genes, duplications in the
SNCA gene (1 PD case WUSTL) or risk-associated variants in
the TREM2, p.R47H (4 WUSTL), GBA, p.N370S (7 WUSTL), or
MAPT, p.A152T (4 WUSTL) genes (Benitez and Cruchaga, 2013;
Benitez et al., 2016) were excluded from this study. Principal
component analyses (PCA) was conducted to infer the genetic
structure of individuals using the EIGENSTRAT software (Price
et al., 2006). Only subjects that clustered with PCs of NHW
origin in the WUSTL or PPMI cohorts were included in this
study.
Sequencing Methods
WUSTL and UN samples: To screen for novel variants, pooled-
DNA sequencing was performed, as described previously (Jin
et al., 2012; Benitez et al., 2016). Briefly, 62 PCR reactions that
covered 46,319 bases of the four selected dementia genes were
performed in two equimolar pools of 114 and 98 samples. After
ligation, concatenated PCR products were randomly sheared
by sonication and prepared for sequencing on an Illumina
Genome Analyzer IIx (GAIIx) according to the manufacturer’s
specifications. The resulting reads were re-aligned to the human
genome reference assembly build 36.1 (hg18) using SPLINTER.
pCMV6-XL5 amplicon (1908 base pairs) was included in the
reaction as a negative control. As positive controls, 10 different
constructs (p53 gene) with synthetically engineered mutations at
a relative frequency of one mutated copy per 200 normal copies
was amplified and pooled with the PCR products. Six human
DNA samples heterozygous for previously known mutations
in GRN and PSEN1genes were also included (Jin et al., 2012;
Benitez et al., 2016). SPLINTER uses the positive control to
estimate sensitivity and specificity for variant calling. The wild-
type: mutant ratio in the positive control is similar to the
relative frequency expected for a single mutation in one pool
(1 chromosome mutated in 100 samples = 1/200). SPLINTER
uses the negative control (first 900 bp) to model the errors
across the 36-bp Illumina reads and to create an error model
from each sequencing run of the machine. Based on the error
model SPLINTER calculates a p-value for the probability that
a predicted variant is a true positive. A p-value at which all
mutants in the positive controls were identified was defined
as the cut-off value for the best sensitivity and specificity. All
mutants included as part of the amplified positive control vector
were found upon achieving ∼30-fold coverage at mutated sites
(sensitivity= 100%) and ∼80 sites in the 1908 bp negative
control vector were predicted to be polymorphic (specificity =
∼95%). The variants with a p-value below this cut-off value were
considered for follow-up confirmation. An average coverage of
30X-fold per haploid genome per pool is the minimum coverage
necessary to get an optimal positive predictive value for the SNP-
calling algorithm (Vallania et al., 2010). Supplementary Table 1
contains a summary of exon coverage per gene. On average, the
coverage was 59.5x per allele per individual, which translate to a
total coverage of ∼13,566x or ∼11,662x depending on the pool
size. All evaluated variants were validated by genotyping with
Sequenom iPLEX or KASPar techniques in all samples. Common
variants (>5%) or synonymous variants were not followed up.
APOE genotype was obtained by direct genotyping of rs7412
and rs429358 using Taqman technology (Cruchaga et al., 2012b).
Most of rare variants were also validated by genome-wide data
generated with the NeuroX custom chip in the WUSTL samples.
NeuroX chip includes both the standard Illumina exome content
(≈ 240,000 variants) and over 24,000 variants associated with
neurologic diseases (Nalls et al., 2015). PPMI Sample: The VCF
files containing the whole exome sequence for all PPMI samples
were downloaded from the PPMI website (www.ppmi-info.org).
The regions of interest for dementia-related genes were extracted
from those files for further analysis. APOE genotype (rs7412 and
rs429358) was obtained from the VCF files.
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Bioinformatics and Statistical Analyses
Annotation and Variant Selection
Variants were annotated using SeattleSeq Annotation (Ng
et al., 2009), the Exome Variant Server (EVS), (http://evs.gs.
washington.edu/EVS/ - Release ESP6500SI-V2), the ExAC data
(release 0.3.1) (Lek et al., 2016) and the Ensembl Genome
browser (Aken et al., 2016). Predictions of variant pathogenicity
were based on the Genomic Evolutionary Rate Profiling (GERP)
(Davydov et al., 2010) and the Combined Annotation Dependent
Depletion (CADD) algorithm (v1.3, http://cadd.gs.washington.
edu) (Kircher et al., 2014). All putative damaging variants (scores
GERP ≥ 2.95 and CADD ≥ 12.37) (Amendola et al., 2015) were
further cross-referenced with The AD&FTD mutation database
(Cruts et al., 2012) and ClinVar (Landrum et al., 2016) to
identify those previously established with pathogenicity for AD
or FTD. Only variants annotated or predicted to be coding
variants [missense, nonsense (stop/start gain/loss) and frameshift
variants] were included in the analyses. Synonymous variants
were not included in our analyses. This analysis was applied
independently to all three cohorts.
Single Variant Analysis
Association analysis between PD cases and in-house controls was
performed using logistic regression, assuming an additive model
for allelic effects. The analysis was adjusted for age, gender, and
PCs (using the first two principal components) to correct for
potential population stratification using Plink1.9 (Purcell et al.,
2007; Chang et al., 2015). The minor allele frequency (MAF)
of each variant in PD cases was also compared with the MAF
described in the Non-Finnish European subgroup (NFE) from
ExAC (Lek et al., 2016). Only coding regions with high-quality
(PASS filter) variants reported in ExAC were included in our
analyses.
Gene Based Analysis
The gene-based association in PD cases and in-house controls
was performed using SKAT-O, which utilizes the R package SKAT
(Wu et al., 2011). In addition, the burden of rare protein-altering
variants in PD cases from the WUSTL and PPMI cohorts were
compared with the burden observed in NFE samples from ExAc
by collapsing the counts of all missense, nonsense and frameshift
variants in each gene with a MAF < 0.01 and then, Fisher’s exact
test with Yates correction was applied. ExAC cannot be regarded
as a pure control dataset. However, several studies have used this
resource as a proxy for reassessing the effect of rare variants in
Mendelian genes in the general population in different complex
diseases (Roberts et al., 2015; Walsh et al., 2017).
Cognitive Impairment Assessment and Analysis
Cognitive impairment was assessed by the Folstein Mini-
Mental State Examination (MMSE) and the Montreal Cognitive
Assessment (MoCA) in the WUSTL and PPMI datasets
respectively. For the combined analyses, z scores were derived
by converting the mean raw MoCA and MMSE scores and
standard deviation (SD) to the standard normal distribution
with mean 0 and SD 1. Multiple regression analyses were
performed in the residuals adjusting by age at diagnosis, age
at dementia assessment, gender, study site and APOE carrier
status as covariates (PROC GLM, SAS). All validated variants
were included in the model independently of their clinical
interpretation. Global cognitive impairment was defined by an
MMSE ≤ 25 according to the recommendation the International
Parkinson and Movement Disorder Society (MDS) Task Force
(Dubois et al., 2007). The recommended MoCA cut-off for PD of
<26 was applied (Dalrymple-Alford et al., 2010). Patients with a
diagnosis of dementia [PPMI (N = 5) andWUSTL (N = 9)] were
excluded from the analyses to avoid disproportionate leverage on
the statistical models (Thaler et al., 2012). Nominally significant
p-value threshold was set at 0.05. Multiple-test correction cutoff
for the single-variant analysis using Bonferroni correction for
4 tests is 1.3 × 10−2. All statistical tests are two-sided unless
otherwise stated, and were performed using Statistical Analysis
System (SAS Institute Inc) or GraphPad Prism 5.0.
APOE Analysis
The effect of APOE allele and genotype in PD risk was tested
comparing the frequency in PD cases and controls. Comparisons
were made using the X2 method. Multiple regression adjusting
by age at diagnosis, age at dementia assessment and gender was
performed to evaluate the effect of APOE ǫ4 allele on MoCA or




Twenty-one coding variants were found among the screened
genes (Supplementary Table 2). 14.3% (3) variants were novel,
4.8% (1) were reported as known pathogenic variants, 19%
(4) were classified as pathogenic nature unclear and 33% (7)
were reported as non-pathogenic. The three novel variants were
PSEN1 (p.P303L), PSEN2 (p.C358R), and GRN (p.A29V). Both
the PSEN1 and PSEN2 variants were found in late-onset PD
individuals whereas the GRN variant was found in one control
(Supplementary Table 3A). The PSEN1 p.A79V mutation (a
known AD pathogenic mutation) was found in three PD cases:
An early-onset PD case (44 years old at onset) and two late-
onset PD cases (75 and 64 years old at onset, respectively).
None of the three carriers reported PD or AD family history.
Neurological evaluation of these three patients at an age of
46, 86, and 82 years revealed no evidence of dementia after 2,
11, and 18 years of disease onset, respectively. The carrier of
the “probable pathogenic” PSEN2, p.S130L variant exhibited an
AAO of 45 years and rapid progression of cognitive impairment
(Supplementary Table 3B).
PPMI Cohort
Eighteen coding variants were found in 5% of the cases and
8.9% of the controls (Supplementary Table 4). 22% (4) of the
variants were novel, 28% (5) were classified as pathogenic nature
unclear and 28% (5) were reported as non-pathogenic; 22%
(4) were reported in public databases but with an unknown
clinical significance. The four variants of unknown significance
included APP (p.R499C), APP (p.R397T), APP (p.Q138R),
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and GRN (p.C260R). Both APP p.R499C and p.R397T were
found in late-onset PD (LOPD; AAO >50 years) patients
whereas APP (p.Q138R) and GRN (p.C260R) were found in
controls (Supplementary Table 5). Five variants in the PSEN2
gene were considered of pathogenic nature unclear for AD:
p.R62H, p.R71W, p.S130L, p.K161R, and p.V393M. Two LOPD
patients carried PSEN2 p.S130L variant and were cognitively
normal at the last clinical assessment (Supplementary Table 5).
Interestingly, the PSEN2 p.R71W variant was present in five
controls and two PD patients achieving nominal significance (p
= 0.01; OR= 0.16; 95% CI = 0.02–0.98).
UN Cohort
Ten coding variants were found in 4.9% of cases from the Spanish
PD cohort. No novel variants were found (Supplementary Table
6). Nine variants were present in the AD/FTDmutation database.
50% (5) of them were considered non-pathogenic, 30% (3) of
them were of pathogenic nature unclear, and 10% (1) of them
(PSEN2 p.V148I) was considered to be pathogenic (Cruts et al.,
2012). The PSEN2 p.V148I carrier is an early onset PD case
(25 years at onset) with a tremor-dominant parkinsonism and
positive family history of PD but dementia-free at last assessment
after 12 years of PD. Seven (1.3%) carriers of the PSEN2 p.S130L
variant were found in Spanish PD patients. Three had positive
PD family history, three had EOPD, three had psychiatric co-
morbidities and two with dementia PD (Supplementary Table
7).
Gene-Based Analysis
The gene-based analysis is a powerful tool to uncover genetic
association. In previous studies, we used gene-based analysis of
the GBA gene in PD and TREM2 in AD to identify additional
variants associated with risk (Jin et al., 2015; Benitez et al., 2016).
SKAT-O analysis revealed that none of the dementia-related
genes achieved statistical significance in the WUSTL series [APP
(p = 0.89), GRN (p = 0.63), PSEN1 (p = 0.13), and PSEN2 (p
= 0.5)] or PPMI [APP (p = 0.15), GRN (p = 0.6), PSEN1 (p =
0.9) and PSEN2 (p = 0.09)] compared with in-house controls
(Supplementary Tables 2, 4). However, joint burden analysis
revealed a significant enrichment of rare variants in the GRN
(6.6 × 10−03; OR = 1.9; 95% CI = 1.2–3.0) and PSEN1 (p = 9.2
× 10−41; OR = 54.2; 95% CI = 18.8–156.1) genes in PD cases
compared with the ExAC NFE cohort (Table 1). The association
of PSEN1 and PD was maintained (p = 4.9 × 10−66) after
excluding the PSEN1 p.A79V mutation from the analysis.
APOE Association With Status and
Cognitive Test Performance
APOE has previously been associated with cognitive impairment
in PD patients (Parsian et al., 2002; Morley et al., 2012; Tsuang
et al., 2013) but APOE effect on PD risk is still controversial
(Federoff et al., 2012). Here, no association was found between
different APOE alleles (ε4 or ε2) and PD case-control status
(Supplementary Tables 8A,B). The APOE ε4 allele was not
associated with lower MoCA scores among PD patients in the
PPMI cohort (p = 0.56). However, consistent with a previous
report, the presence of the APOE ε4 allele was associated with
TABLE 1 | Enrichment of rare variants in the PSEN1 and GRN genes in PD
patients.
Gene cMAF* PD Cases cMAF ExACϕ p-value# OR (95% CI)#
APP 0.0004 0.0004 ns§ -
GRN 0.0010 0.0005 6.6 × 10−03 1.9 (1.2–3.0)
PSEN1 0.0010 0.00002 9.1 × 10−41 54.2 (18.8–156.1)
PSEN2 0.0010 0.0010 ns -
*cMAF= cumulative minor allele frequency of all non-synonymous variants in each gene.
ϕNon-Finnish European ExAC individuals.
#WUSTL and PPMI PD cases vs ExAC non-Finish Europeans controls.
§Not statistically significant.
a lower MMSE score (p = 9.0 × 10−3) in WUSTL PD patients
(Parsian et al., 2002).
Effect of Variants in Dementia-Causing
Genes on Cognitive Tests Performance
Several rare variants in the GBA gene have been associated
with lower MMSE scores in PD patients (Liu et al., 2016). We
hypothesized that variants in the dementia-causing genes would
affect performance on cognitive tests. Interestingly, 4.9% of all PD
patients in the PPMI cohort carrying rare variants in dementia-
causing genes exhibit significantly (p= 3.0× 10−2) lower MoCA
scores than non-carriers PD patients (Figure 1A). Similarly, PD
patients carrying rare variants in dementia-causing genes (7.9%
of all patients) exhibit significantly (p= 2.0× 10−3) lowerMMSE
scores than non-carriers in the WUSTL cohort (Figure 1B).
Cognitive impairment was assessed with a different cognitive test
in each cohort included in this study (MMSE for WUSTL and
MoCA for PPMI). Therefore, we perform a combined analysis
with age at PD diagnosis, age at which the dementia test was
performed, APOE status, and cohort included as covariates.
PD patients carrying rare variants in dementia-causing genes
exhibited lower scores on cognitive tests than non-carrier PD
patients (p = 2.0 × 10−4), independent of age at PD diagnosis,
age at evaluation, APOE status or cohort (Table 2).
DISCUSSION
The genetic architecture of dementia in PD has not yet been
fully established. Genetic variants in APOE and MAPT have
time-dependent effects on cognition, which vary with disease
stage: MAPT appears to have its greatest impact on cognitive
decline in early PD, whereas APOEmay have a more pronounced
effect late in the course of the disease (Collins and Williams-
Gray, 2016). A recent GWAS on an extensive neuropsychological
battery in PD patients failed to replicate prior associations with
APOE, MAPT, catechol-O-methyltransferase (COMT), or SNCA
(Mata et al., 2017). In cross-sectional studies, the prevalence of
dementia in GBA-PD cases is about 50%, compared to 24–31%
in idiopathic PD cases (Setó-Salvia et al., 2012). Longitudinal
studies have confirmed a faster progression to dementia in PD
cases carrying GBA mutations compared to idiopathic PD in a
population-representative cohort followed for ∼10 years from
diagnosis (Winder-Rhodes et al., 2013). However, GBA variants
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FIGURE 1 | Effect of variants in APP, GRN, PSEN1, and PSEN2 genes on cognitive test scores in PD patients. (A), Tukey’s boxplot of MoCA scores in PD
non-carriers vs. PD carriers of variants in the dementia-causing genes in the PPMI cohort. (B), Tukey’s boxplot of the MMSE scores in non-carriers and carriers of
variants in the dementia-causing genes in the PD cases of the WUSTL cohort. Student’s t-test was used and p-values reported are based on two-tailed comparisons.
TABLE 2 | Effect of rare variants in dementia-causing genes on cognitive test








Age at PD Dx§ 0.006 0.009 0.64 0.5225
Age at
assessment
−0.015 0.009 −1.64 0.1018
APOE* −0.039 0.041 −0.96 0.3385
Carrier status# −0.684 0.180 −3.80 0.0002
Recruitment sitesϕ 0.223 0.142 1.58 0.1153
§Dx = diagnostic.
ϕCombined analysis MoCA and MMSE.
*APOE genotype 22 = 0, 23 = 1, 33 = 2, 24 = 3, 34 = 4, and 44 = 5.
#0 = non carrier, 1 = carrier.
ϕ0 = PPMI, 1 = WUSTL.
explained only up to 1.4% of PD patients with cognitive decline
(Liu et al., 2016). Our results show that 6.7% of PD patients carry
rare coding variants in dementia-causing genes and exhibit lower
scores on cognitive tests in two independent cohorts compared to
non-carriers. The risk of developing dementia varies according
to the duration of PD and age at onset (Rocca et al., 2007).
However, the results of a covariate-adjusted model confirm that
the association between rare variants in dementia-causing genes
and lower scores in cognitive tests appears to be independent of
age, cohort, disease duration, or APOE status.
The APOE ε4 allele has been associated with a higher
prevalence of dementia in PD (Morley et al., 2012; Tsuang
et al., 2013). The small number of PD cases with dementia in
each study, the significant heterogeneity of odds ratios between
studies, and evidence of publication bias limits the confidence
of the APOE and dementia in PD association (Huang et al.,
2006). In this study, the APOE ε4 allele was not associated with
risk of developing PD in none of the cohorts (Supplementary
Tables 8A,B). However, in the WUSTL cohort, APOE ε4 carriers
exhibited lower scores on cognitive tests, but the PPMI cohort did
not replicate these findings. Therefore, further studies are needed
to clarify the role of APOE in PD cognitive impairment (Parsian
et al., 2002).
The wide variation reported in the prevalence of cognitive
impairment (CI) in PD across studies may be due to the cognitive
tests employed (Goldman and Litvan, 2011; Burdick et al., 2014).
The MMSE and MoCA are the most commonly used tests
to assess CI in PD. However, controversy remains regarding
the sensitivity of MMSE in assessing cognition in PD patients
(Burdick et al., 2014). Even though the MoCA is more sensitive
for detecting cognitive changes in PD patients (Hoops et al.,
2009), the MMSE was the cognitive test that showed the effects
of GBA and LRRK2 mutations on CI in PD patients (Srivatsal
et al., 2015; Liu et al., 2016) and is the cognitive test recommended
by the International Parkinson and Movement Disorder Society
Task Force (Dubois et al., 2007). Nevertheless, here we show that
rare variants in dementia-related genes affect both MMSE and
MoCA scores in two heterogeneous PD populations (p = 2.0 ×
10−4; Table 2).
In addition, 0.3% of all PD patients screened in this study
carry known AD pathogenic variants in PSEN1 and PSEN2
genes (Supplementary Tables 2, 6). A frequency of 0.3% is
comparable to the percentage of PD patients carrying the most
common pathogenic mutation (LRRK2 p.G2019S) known for
sporadic PD (0.4–1%) (Healy et al., 2008; Correia Guedes et al.,
2010). None of the PD patients carrying pathogenic mutations
in PSEN1 and PSEN2 exhibited signs of dementia at their last
clinical assessment. Unfortunately, CSF biomarkers or Pittsburgh
compound B (PiB) imaging were not available from these carriers
to help determine their preclinical status. The PSEN1 p.A79V
mutation is associated with a broad range of AAO in AD and
DLB patients (Cruchaga et al., 2012a; Meeus et al., 2012b). PSEN1
p.A79V is found in non-demented carriers at an AAO as late
as 78 years (Kauwe et al., 2007) and, in some multigenerational
AD families, it does not segregate perfectly with disease status
(Cruchaga et al., 2012a). However, the PSEN1 p.A79V mutation
increases the Aβ42 level and Aβ42/Aβ40 ratio in vitro (Kumar-
Singh et al., 2006; Kauwe et al., 2007) but unlike other PSEN1
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mutations that cause massive Aβ42 deposition, the average
Aβ42 brain deposition in sporadic AD patients exceeded those
observed in the brains of p.A79V carriers (Kumar-Singh et al.,
2006). In addition, non-demented p.A79V carriers also exhibit
changes in CSF Aβ42 levels and the Aβ42/40 ratio with no
evidence of β-amyloid deposition using PiB imaging (Kauwe
et al., 2007). Thus, PSEN1 p.A79V may be acting through a
mechanism other than increasing Aβ deposition. Additional
mutations in the PSEN1 gene including p.G217D, p.V272A, and
p.L420R have been associated with dementia and parkinsonism
(Takao et al., 2002; Jimenez-Escrig et al., 2004; Puschmann et al.,
2009; Niwa et al., 2013). Recently, it was reported that a de novo
PSEN1 mutation is responsible for an early-onset parkinsonism
with cognitive impairment (Carecchio et al., 2017). In addition
to the clinical overlap between dementia and parkinsonism
in carriers of PSEN1 mutations, there is extensive Lewy body
pathology in early-onset AD carriers of the PSEN1 p.S170F
(Snider et al., 2005) and PSEN1 p.A431V mutations (Qiao et al.,
2017) suggesting an interaction between PSEN1 dysfunction and
α-synuclein aggregation.
We also found the PSEN2 p.V148I mutation in a Spanish PD
patient but not in 550 age-matched Spanish controls. The PSEN2
p.V148I mutation was originally reported in a Spanish patient
with late-onset AD (AAO = 71 years) (Lao et al., 1998) but,
its pathogenicity has been questioned based on the absence of
effect on either Aβ42 levels, Aβ40 levels, or the Aβ42/40 ratio
in vitro (Walker et al., 2005). However, some variants that show
no effect on Aβ42 levels or the Aβ42/Aβ40 ratio (Walker et al.,
2005) affect calcium signaling in cultured skin fibroblasts from
mutation carriers (Li et al., 2006). Increasing evidence suggests
a role of the PSEN2 p.S130L variant in PD and dementia. Here,
we found a total of nine PD patients and one control carrying
the “probably pathogenic” PSEN2 p.S130L variant. The PSEN2
p.S130L variant has been reported in patients with late-onset AD
and mild bradykinesia (Tomaino et al., 2007; Lohmann et al.,
2012). Two siblings of a PSEN2 p.S130L carrier AD patient were
diagnosed with PD (Tomaino et al., 2007). Recently, PSEN2
p.S130L was reported in an individual with idiopathic PD with
dementia (AAO = 73 years) (Schulte et al., 2015). Another
mutation in PSEN2 (p.V191E) also was found in one late-onset
PD patient (AAO= 75 years) with cognitive decline (Meeus et al.,
2012b). Interestingly, a Swedish PD family who carry a de novo
α-synuclein p.A53T mutation also carried the PSEN2 p.R163H
variant (Puschmann et al., 2009). Carriers of both mutations
develop early-onset dementia (Puschmann et al., 2009). All
these findings support our data that pathogenic variants in the
presenilin genes are present in a small proportion of sporadic PD
patients and contribute to α-synuclein aggregation.
We found an enrichment of rare variants in the GRN gene
in PD patients compared to the general population (ExAC
NFE). The frequencies of the p.R433W and p.R478H variants
were higher in the WUSTL cohort than in the NFE ExAC
cohort. Interestingly, the variant p.R433W was reported in
neuropathologically confirmed LBD cases (Meeus et al., 2012b).
Mutations in the GRN gene occur in LBD patients (Meeus
et al., 2012b). A heterozygous deletion removing exons 1 to 11
of the GRN gene was reported in an 83 year-old PD patient
(Rovelet-Lecrux et al., 2008) and, the IVS0 + 5G>C mutation
was reported in a 56 year-old PD patient (Brouwers et al.,
2007). In addition, parkinsonism occurs in some FTD patients
and is more common in those patients (up to 41%) with
GRN haploinsufficiency (Josephs et al., 2007). Interestingly, GRN
overexpression in the substantia nigra protected nigrostriatal
neurons in a mouse model of PD (Van Kampen et al., 2014).GRN
seems to play an important role in multiple neurodegenerative
diseases including PD, likely due to its function as a neurotrophic
factor and its recently uncovered lysosome function (Tanaka
et al., 2013).
Low frequency and rare mutations in the GBA gene,
which encodes the lysosomal enzyme β-glucocerebrosidase-1,
consistently relate to CI in PD and to Lewy body dementia
(Nalls et al., 2013). α-synuclein is mainly degraded by lysosomes
(Cuervo et al., 2004) and lysosomal dysfunction may contribute
to de novo aggregation of α-synuclein and impaired autophagic
degradation of cytosolic aggregates (Bourdenx et al., 2014).
LBs and Lewy neurites may seed around impaired lysosomes
and grow in size by continuous deposition of lysosomal-
derived un-degraded material as the disease progresses (Dehay
et al., 2013). Thus, considering that presenilin and granulin are
lysosomal proteins (Sannerud et al., 2016; Kao et al., 2017), it
is logical to suggest that variants in the presenilin or granulin
genes may exacerbate the cognitive impairments in PD by
affecting lysosomal function and facilitating cell-to-cell transfer
of proteopathic seeds in the progression of synucleinopathies.
The relatively small size of this study limits the statistical
power, which could be the reason we failed to find significant
associations between the PD cases and the in-house controls.
However, the inclusion of the large NFE ExAC cohort with
similar genetic background minimized this limitation. The data
used in this study were not generated using a single sequencing
method. However, none of the approaches used were expected
to have 100% sensitivity for variant detection. Although these
technical limitations could have marginal effects on estimates of
rare variant frequency and odds ratio values, we do not expect
them to alter the key conclusions of this study. Further studies
are needed to confirm the role of variants in dementia genes in
the cognitive impairment found in PD patients.
CONCLUSION
Our study shows that rare variants in several dementia-related
genes are enriched in PD patients compared with normal
controls. The PD patients with these variants exhibited lower
cognitive performance than PD patients without these variants.
Moreover, known dementia-causing mutations are found in PD
patients.
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